Literature DB >> 24359765

Prognostic usefulness of left ventricular hypertrophy by electrocardiography in patients with atrial fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study).

Paolo Verdecchia1, Gianpaolo Reboldi2, Giuseppe Di Pasquale3, Giovanni Mazzotta4, Giuseppe Ambrosio4, Sean Yang5, Janice Pogue5, Lars Wallentin6, Michael D Ezekowitz7, Stuart J Connolly5, Salim Yusuf5.   

Abstract

It is unknown whether left ventricular hypertrophy (LVH) diagnosis by electrocardiography improves risk stratification in patients with atrial fibrillation (AF). We investigated the prognostic impact of LVH diagnosis by electrocardiography in a large sample of anticoagulated patients with AF included in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Study. We defined electrographic LVH (ECG-LVH) by strain pattern or Cornell voltage (R wave in aVL plus S wave in V3) >2.0 mV (women) or >2.4 mV (men). LVH prevalence was 22.7%. During a median follow-up of 2.0 years, 303 patients developed a stroke, 778 died (497 from cardiovascular causes), and 140 developed a myocardial infarction. LVH was associated with a greater risk of stroke (1.99% vs 1.32% per year, hazard ratio [HR] 1.51, 95% confidence interval [CI] 1.18 to 1.93, p <0.001), cardiovascular death (4.52% vs 1.80% per year, HR 2.56, 95% CI 2.14 to 3.06, p <0.0001), all-cause death (6.03% vs 3.11% per year, HR 1.95, 95% CI 1.68 to 2.26, p <0.0001), and myocardial infarction (1.11% vs 0.55% per year, HR 2.07, 95% CI 1.47 to 2.92, p <0.0001). In multivariate analysis, the prognostic value of LVH was additive to CHA2DS2-VASc score and other covariates. The category-free net reclassification index and integrated discrimination improvement increased significantly after adding LVH to multivariate models. In conclusion, our study demonstrates for the first time that ECG-LVH, a simple and easily accessible prognostic indicator, improves risk stratification in anticoagulated patients with AF.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24359765     DOI: 10.1016/j.amjcard.2013.10.045

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  A Review of the Relationship of Atrial Fibrillation and Acute Coronary Syndrome.

Authors:  Bory Kea; Tahroma Alligood; Vincent Manning; Merritt Raitt
Journal:  Curr Emerg Hosp Med Rep       Date:  2016-07-06

2.  Electrocardiographic left ventricular hypertrophy predicts recurrence of atrial arrhythmias after catheter ablation of paroxysmal atrial fibrillation.

Authors:  Song-Nan Li; Lu Wang; Jian-Zeng Dong; Rong-Hui Yu; De-Yong Long; Ri-Bo Tang; Cai-Hua Sang; Chen-Xi Jiang; Nian Liu; Rong Bai; Xin Du; Chang-Sheng Ma
Journal:  Clin Cardiol       Date:  2018-06-05       Impact factor: 2.882

Review 3.  Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.

Authors:  Miho Kimachi; Toshi A Furukawa; Kimihiko Kimachi; Yoshihito Goto; Shingo Fukuma; Shunichi Fukuhara
Journal:  Cochrane Database Syst Rev       Date:  2017-11-06

4.  Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society.

Authors:  Giuseppe Boriani; Irina Savelieva; Gheorghe-Andrei Dan; Jean Claude Deharo; Charles Ferro; Carsten W Israel; Deirdre A Lane; Gaetano La Manna; Joseph Morton; Angel Moya Mitjans; Marc A Vos; Mintu P Turakhia; Gregory Y H Lip
Journal:  Europace       Date:  2015-06-24       Impact factor: 5.214

5.  Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation- the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study.

Authors:  Paolo Verdecchia; Gianpaolo Reboldi; Fabio Angeli; Giovanni Mazzotta; Gregory Y H Lip; Martina Brueckmann; Eva Kleine; Lars Wallentin; Michael D Ezekowitz; Salim Yusuf; Stuart J Connolly; Giuseppe Di Pasquale
Journal:  Europace       Date:  2018-02-01       Impact factor: 5.214

6.  Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the  RE - LY Trial.

Authors:  Ziad Hijazi; Paolo Verdecchia; Jonas Oldgren; Ulrika Andersson; Gianpaolo Reboldi; Giuseppe Di Pasquale; Giovanni Mazzotta; Fabio Angeli; John W Eikelboom; Michael D Ezekowitz; Stuart J Connolly; Salim Yusuf; Lars Wallentin
Journal:  J Am Heart Assoc       Date:  2019-01-22       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.